Oncopeptides AB (publ)
ONCO
Rank in Stocks
#20709
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical... Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate engineered to address multiple myeloma that has relapsed or become resistant to prior treatments in adult individuals. Founded in 2000, Oncopeptides AB (publ) conducts its main business from Stockholm, Sweden.
Share Price
$0.18527947
Last synced: 2026-11-09
Market Cap
$79.92M
Change (1 day)
5.09%
Change (1 year)
-64.16%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oncopeptides AB (publ) (ONCO)
Category
Healthcare
Operating Margin for Oncopeptides AB (publ) (ONCO)
Operating Margin as of November 2026 TTM: -211.09%
According to Oncopeptides AB (publ)'s latest financial reports, its current operating margin (TTM) is -211.09%. At the end of 2025 the company had an operating margin of -317.62%.
Operating Margin history for Oncopeptides AB (publ) from 2014 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -211.09% | -33.54% |
| 2025 | -317.62% | -64.54% |
| 2024 | -895.78% | 24.48% |
| 2023 | -719.61% | -82.79% |
| 2022 | -4,181.33% | 248.11% |
| 2021 | -1,201.16% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.18% |
US
|
|
| -149.01% | -99.29% |
US
|
|
| 25.57% | -100.12% |
AU
|
|
| 31.23% | -100.15% |
BE
|
|
| 29.35% | -100.14% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Oncopeptides AB (publ)'s operating margin
What is Oncopeptides AB (publ)'s operating margin?
Oncopeptides AB (publ)'s operating margin is -211.09%, as of Nov 2026.
What was Oncopeptides AB (publ)'s operating margin in 2025?
In 2025, Oncopeptides AB (publ)'s operating margin was -317.62%, compared with -895.78% in 2024.
How has Oncopeptides AB (publ)'s operating margin changed since 2020?
From 2020 to 2025, Oncopeptides AB (publ)'s operating margin was highest in 2020 (0.00%) and lowest in 2022 (-4,181.33%).
How does Oncopeptides AB (publ)'s operating margin compare with similar companies?
Oncopeptides AB (publ)'s operating margin (-211.09%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.